Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
A retrospective medical database analysis of T2D patients (n = 39,275) treated with exenatide or other glucose-lowering therapies (n = 381,218) indicated that the GLP-1 agonist might reduce in 19% the incidence of MACCE and in 12% cardiovascular hospitalizations [71]
doi: 10.1016/j.celrep.2021.109753 72 LachnerCSteinleNIRegenoldWT
This raises a theoretical concern about hypoglycemia when combined with insulin, sulfonylureas, or other glucose-lowering agents
Look for savings Eligible patients may qualify for manufacturer savings programs or third-party discount options
US$ 20.65
US$ 22.13
US$ 23.42
US$ 29.03
